cancer Page 4

Keyword: cancer

102 results found
Copyright_Wavebreak Media Ltd_123RF

When a 46-year-old woman was diagnosed in early 2016 with stage-two triple-negative breast cancer, she started planning her return to full-time work at almost the same time she began treatment. “It’s interesting because when we think of return-to-work planning, we think of starting to talk about this toward the end of the treatment phase,” said […]

Webinar: Current health-care policies impacting private drug coverage

On May 12, Benefits Canada hosted a webinar to discuss the pharmaceutical industry’s efforts during the coronavirus crisis, as well as some key policy issues for Canadian insurers and their potential impact from the private-payer perspective. Since the end of April, 139 coronavirus treatments have been under investigation and Health Canada has approved several clinical trials […]

Specialty drug usage, traditional drug costs drive small rise in 2019 spending: report

Private drug plans saw a slight uptick in costs in 2019 due to the increased use of specialty drugs and higher price points for traditional medications, according to Express Scripts Canada’s annual drug trends report. The report found private drug plan spending per claimant increased one per cent over 2018’s figures. Plans’ annual spend per claimant on […]

  • By: Staff
  • April 14, 2020 September 15, 2022
  • 10:00
Conference coverage: 2020 Employers Cancer Care Summit

On March 3, the 2020 Employers Cancer Care Summit featured sessions on cancer-related issues and opportunities tied to benefits plans and the workplace. Many perspectives required when covering cancer drugs on benefits plans While treatment options for cancer are more than they used to be, many still aren’t covered under the public health-care system, according to Tim […]

Many perspectives required when covering cancer drugs on benefits plans

While treatment options for cancer are more than they used to be, many still aren’t covered under the public health-care system, according to Tim Clarke, president of TC Health Consulting Inc. In a session at Benefits Canada’s 2020 Employers Cancer Care Summit on Mar. 3, he said employer costs for cancer drug treatments have doubled between […]

Immunotherapy innovations beneficial in kidney cancer treatment

While kidney cancer is uncommon in patients younger than age 45, there’s an increasing incidence in diagnosis in young people because of the advent of imaging technology, according to Dr. Nazanin Fallah-Rad, medical oncologist at Princess Margaret Cancer Centre and Mount Sinai Hospital. “There’s an increasing incidence of younger people being diagnosed with kidney cancer and […]

Flexible return-to-work policies crucial for cancer survivors

By the year 2031, 2.2 million Canadians will be living with cancer, with 40 per cent between the ages of 20 and 65 — the typical working years, according to Maureen Parkinson, provincial rehabilitation counsellor at B.C. Cancer Agency and co-director of Cancer and Work. In a session at Benefits Canada’s 2020 Employers Cancer Care […]

Fidelity Canada touts preventative, life-sustaining benefits plans

When it comes to benefits plan management, each case is individual, said Diana Godfrey, senior vice-president of human resources and corporate at Fidelity Canada, during a session at Benefits Canada’s 2020 Employers Cancer Care Summit on Mar. 3. “If employers think they have a program or policy that covers every situation, they may be mistaken.” […]

Ignoring psychosocial oncology can be costly for organizations

When a person experiences a cancer diagnosis and undergoes treatment, it can be one of the most distressing experiences they can go through, so it’s important for employers to understand psychosocial oncology. “We’re now collecting evidence to show that proactive care — psychosocial oncology — is effective in helping people prepare and deal with psychological […]

2020 Drug Plan Trends Report: Developments, data and design

Taking a look at private drug plans in 2020, a number of trends are converging: spending on specialty drugs is continuing its upward trajectory, advancements in a number of lifechanging therapies are in the pipeline and policy developments are coming at both the federal and provincial levels. In the face of this potential storm, plan […]